The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer

Xiaohua LU; Hongxin YUAN

doi:10.12259/j.issn.2095-610X.S20230927

Volume 44 Issue 9

Sep. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2023 > 44(9): 126-135

Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer[J]. Journal of Kunming Medical University, 2023, 44(9): 126-135. doi: 10.12259/j.issn.2095-610X.S20230927

Citation:

Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer[J]. Journal of Kunming Medical University, 2023, 44(9): 126-135. doi: 10.12259/j.issn.2095-610X.S20230927

Citation:

Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer[J]. Journal of Kunming Medical University, 2023, 44(9): 126-135. doi: 10.12259/j.issn.2095-610X.S20230927

PDF( 898 KB)

The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer

doi: 10.12259/j.issn.2095-610X.S20230927

Xiaohua LU,
Hongxin YUAN^,

Dept. of Interventional Radiology，Affiliated Hospital of Nantong University， Nantong Jiangsu 226001，China

Received Date: 2023-04-13
Available Online: 2023-09-22
Publish Date: 2023-09-30

Abstract

Abstract

Objective To investigate the correlation between gene polymorphisms of B and T lymphocyte attenuator （BTLA） and cytotoxic T lymphocyte antigen-4 （CTLA-4） and the efficacy and prognosis of targeted therapy combined with transcatheter arterial chemoembolization （TACE） for liver cancer. Methods Eighty-five new hepatocellular carcinoma patients admitted to the Department of Interventional Radiology of Nantong University Hospital between 2021-01-01 and 2021-12-31 were selected for the study, and all of them were treated with TACE combined with targeted therapy. According to the RECIST solid tumor efficacy evaluation criteria, the patients were divided into the effective treatment group （n = 58） and the disease progression group （n = 27）. The clinical data, BTLA, CTLA-4 gene polymorphisms between the 2 groups were compared and the correlation between BTLA, CTLA-4 gene polymorphisms and efficacy were analyzed, And follow-up survival status by phone at 18 months after the treatment was conducted to compare the survival status of patients with different genotypes, and analyze their correlation with survival prognosis. Results CTLA-4 rs231775, rs733618, rs3087243, rs4553808, BTLA and the genotypes of rs2171513, rs3112270, rs1982809 and rs16859629 all conformed to Hardy-Weinberg law of genetic balance. The BTLA rs3112270 AG, GG genotype ratio, rs1982809 GA, AA ratio, rs16859629 CC genotype, CTLA-4 rs231775 AA genotype ratio, rs3087243 GA, AA genotype ratio in the treatment effective group were all lower than those in the disease progression group, while the proportion of AA genotype at BTLA rs3112270, GG genotype at rs1982809, TT genotype at rs16859629, GG genotype at CTLA-4 rs231775, and GG genotype at rs3087243 were all higher than those in the disease progression group （P < 0.05）; Univariate and multivariate analysis showed that BTLA rs3112270 A > G, rs1982809 G > A, rs16859629 T > C, CTLA-4 rs231775 A > G, rs3087243 G > A were all associated with the efficacy （P < 0.05）; The 18 month survival rate of BTLA rs3112270 AA and AG genotype patients was higher than that of GG genotype patients, rs1982809 GG and GA genotype patients were higher than that of AA genotype patients, and rs16859629 TT genotype patients are higher than those of TC and CC genotype patients （P < 0.05）; The 18 month survival rate of patients with CTLA-4 rs231775 GG and GA genotypes was higher than that of patients with AA genotypes, and the 18 month survival rate of GG genotype at rs3087243 was higher than that of patients with GA and AA genotypes （P < 0.05）; Univariate and multivariate analysis showed that BTLA rs3112270 A > G, rs1982809 G > A, rs16859629 T > C, CTLA-4 rs231775 A > G, rs3087243 G > A were all associated with the survival prognosis （P < 0.05）. Conclusion The polymorphisms of BTLA gene rs3112270, rs1982809, rs16859629, CTLA-4 gene rs231775, rs3087243 are closely related to the efficacy and prognosis of TACE combined with the targeted therapy for liver cancer and these will provide the reference for predicting TACE treatment.
- BTLA,
- CTLA-4,
- Gene polymorphism,
- Liver cancer,
- TACE,
- Targeted therapy,
- Curative effect,
- Prognosis,
- Correlation

FullText(HTML)

References(26)

References

[1]	Xia C,Dong X,Li H,et al. Cancer statistics in China and United States,2022: Profiles,trends,and determinants[J]. Chin Med J (Engl),2022,135(5):584-590. doi: 10.1097/CM9.0000000000002108
[2]	Sung H,Ferlay J,Siegel R L,et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249. doi: 10.3322/caac.21660
[3]	Yu Y,Fu J,Xia P,et al. A systematic review and meta-analysis on the efficacy and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of primary liver cancer[J]. Transl Cancer Res,2022,11(5):1297-1308. doi: 10.21037/tcr-22-816
[4]	Shao L,Wang X,Yu Y,et al. Comparative analysis of the efficacy and accuracy of magnetic resonance imaging (MRI) and contrast-enhanced CT for residual and new lesions after transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer[J]. Transl Cancer Res,2021,10(8):3739-3747. doi: 10.21037/tcr-21-831
[5]	Zhong Y,Xu F,Wu J,et al. Application of next generation sequencing in laboratory medicine[J]. Ann Lab Med,2021,41(1):25-43. doi: 10.3343/alm.2021.41.1.25
[6]	Chen J,Wang J,Liu R,et al. The correlation of BTLA rs1982809 polymorphism with cancer susceptibility: A meta-analysis of 8634 participators[J]. Medicine (Baltimore),2022,101(31):e29610.
[7]	Chen J,Kang S,Wu J,et al. CTLA-4 polymorphism contributes to the genetic susceptibility of epithelial ovarian cancer[J]. J Obstet Gynaecol Res,2022,48(5):1240-1247. doi: 10.1111/jog.15186
[8]	《原发性肝癌诊疗规范(2019年版)》编写专家委员会. 原发性肝癌诊疗规范(2019年版)[J]. 中国临床医学,2020,27(1):140-156.
[9]	杨学宁,吴一龙. 实体瘤治疗疗效评价标准-RECIST[J]. 循证医学,2004,4(2):85-90,111. doi: 10.3969/j.issn.1671-5144.2004.02.012
[10]	Zhang C,Dai Y H,Lian S F,et al. Efficacy of transcatheter arterial chemoembolization using pirarubicin-loaded microspheres combined with lobaplatin for primary liver cancer[J]. World J Clin Cases,2022,10(27):9650-9656. doi: 10.12998/wjcc.v10.i27.9650
[11]	Huh J,Kim B,Lee J H,et al. Added value of CT arterial subtraction images in liver imaging reporting and data system treatment response categorization for transcatheter arterial chemoembolization-treated hepatocellular carcinoma[J]. Invest Radiol,2021,56(2):109-116. doi: 10.1097/RLI.0000000000000714
[12]	Vosshenrich J,Zech C J,Heye T,et al. Response prediction of hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: Unlocking the potential of CT texture analysis through nested decision tree models[J]. Eur Radiol,2021,31(6):4367-4376. doi: 10.1007/s00330-020-07511-3
[13]	Zhang H,Fu L. The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment[J]. Acta Pharm Sin B,2021,11(6):1400-1411. doi: 10.1016/j.apsb.2021.02.008
[14]	Wang Y,Xia X B,Tang H Z,et al. Association of T2285C polymorphism in PARP1 gene coding region with its expression,activity and NSCLC risk along with prognosis[J]. Mutagenesis,2021,36(4):281-293. doi: 10.1093/mutage/geab022
[15]	Herrero Rivera D,Vacas C G,Kovandzic L M,et al. Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel[J]. Pharmacogenomics,2022,23(11):627-638. doi: 10.2217/pgs-2022-0023
[16]	刘绍灵,彭国璇,邓进. BTLA基因与炎症免疫调控研究进展[J]. 创伤外科杂志,2017,19(7):555-557. doi: 10.3969/j.issn.1009-4237.2017.07.025
[17]	Kraehenbuehl L,Weng C H,Eghbali S,et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways[J]. Nat Rev Clin Oncol,2022,19(1):37-50. doi: 10.1038/s41571-021-00552-7
[18]	Khadhraoui C,Kaabachi W,Tritar F,et al. Association of BTLA rs1982809 polymorphism with lung cancer risk in Tunisian population[J]. Int J Immunogenet,2020,47(6):554-562. doi: 10.1111/iji.12491
[19]	Fu Z,Li D,Jiang W,et al. Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang province[J]. Breast Cancer Res Treat,2010,120(1):195-202. doi: 10.1007/s10549-009-0462-6
[20]	王居巳. BTLA基因多态性在非小细胞肺癌易感性方面的关联性分析[D]. 福州: 福建医科大学硕士学位论文, 2021.
[21]	Ui A,Chiba N,Yasui A. Relationship among DNA double-strand break (DSB),DSB repair,and transcription prevents genome instability and cancer[J]. Cancer Sci,2020,111(5):1443-1451. doi: 10.1111/cas.14404
[22]	Zhang H,Dai Z,Wu W,et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer[J]. J Exp Clin Cancer Res,2021,40(1):184. doi: 10.1186/s13046-021-01987-7
[23]	刘琦,赵灵燕,程佳颖,等. CTLA-4基因多态性与肾癌易感性的相关性研究[J]. 实用癌症杂志,2021,36(3):497-500. doi: 10.3969/j.issn.1001-5930.2021.03.039
[24]	Najafi A,Alizadeh-Navaei R,Rahimi S,et al. Genetic polymorphisms of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and clinical outcomes post-allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis[J]. Clin Transplant,2021,35(8):e14364. doi: 10.1111/ctr.14364
[25]	Liu X,Swen J J,Diekstra M H M,et al. A genetic polymorphism in CTLA-4 is associated with overall survival in sunitinib-treated patients with clear cell metastatic renal cell carcinoma[J]. Clin Cancer Res,2018,24(10):2350-2356. doi: 10.1158/1078-0432.CCR-17-2815
[26]	Qin X Y,Lu J,Li G X,et al. CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens[J]. Ann Hematol,2018,97(3):485-495. doi: 10.1007/s00277-017-3203-7

Relative Articles(20)

Relative Articles

[1]	Liyuan YUN, Junfeng WANG, Ning GUO, Ruimei DING, Haipeng LI, Xueping ZHANG. Analysis of the Efficacy and Safety of GM1 Injection Combined with Batroxobin in the Treatment of Sudden Deafness Patients. Journal of Kunming Medical University, 2024, 45(6): 140-144. doi: 10.12259/j.issn.2095-610X.S20240619
[2]	Lanzhu YAN, Shunyi QIAO, Yanli ZHANG, Erqiang ZHAO, Hu YANG, Jing LIN, Haiyan FU. Changes of Immunoglobulin in TACE Treatment of Hepatocellular Carcinoma and Its Value in Predicting Curative Effect. Journal of Kunming Medical University, 2024, 45(4): 128-134. doi: 10.12259/j.issn.2095-610X.S20240418
[3]	Changmeng HU, Lin WU. Correlation Between Silva Type and Prognosis of Cervical HPV-associated Adenocarcinoma. Journal of Kunming Medical University, 2022, 43(8): 113-121. doi: 10.12259/j.issn.2095-610X.S20220817
[4]	Xi GUO, Xiaoqing TANG, Jie WANG, Yan WAN, Bin XU, Yu LUO. Effect of Early Interventional Palliative Treatment on Pain and Anxiety in Patients with Hepatitis-Related Liver Cancer. Journal of Kunming Medical University, 2022, 43(8): 93-99. doi: 10.12259/j.issn.2095-610X.S20220813
[5]	Xin-yuan CHEN, Hui WU, Ya-xiong MO, Yan-bing HAN, Xin-li CHEN, Wen-ye ZHU, Rui HUANG, Wen TANG. Association between NRG1-Erbb4 Polymor- phism and Focal Epilepsy. Journal of Kunming Medical University, 2021, 42(6): 82-87. doi: 10.12259/j.issn.2095-610X.S20210607
[6]	Hao-hao WU, Jun-su YANG, Bao-gang HUANG, Shao-yong GUAN, Yan ZHENG, Hui-juan FAN. Efficacy and Prognosis of Levetiracetam Injection in the Treatment of Convulsive Status Epilepsy. Journal of Kunming Medical University, 2021, 42(10): 151-156. doi: 10.12259/j.issn.2095-610X.S20211031
[7]	Ou Yang Pei Gang , Zhang Gui Min , Liu Yin Qiang . . Journal of Kunming Medical University, 2019, 40(07): 25-29.
[8]	Pan Zi Peng . Analysis and Safety Evaluation of the Clinical Efficacy of Laparoscopic Appendectomy for Acute Appendicitis. Journal of Kunming Medical University,
[9]	Huang Hong . The Correlation of ACE I/D Gene Polymorphisms with the Antihypertensive Efficacy of Irbesartan Among Hypertensive Patients. Journal of Kunming Medical University,
[10]	Tong Yu Yun . Clinical Application of Iodine Oil-Docetaxel-Suspension in Transcatheter Arterial Chemoembolization for Primary Hepatic Carcinoma. Journal of Kunming Medical University,
[11]	Liu Ju Peng . . Journal of Kunming Medical University,
[12]	Zeng Hai Ping . . Journal of Kunming Medical University,
[13]	Ma Lin . . Journal of Kunming Medical University,
[14]	He Zhi Jiang . . Journal of Kunming Medical University,
[15]	Wang Zhu Jun . . Journal of Kunming Medical University,
[16]	Xia Yao You . . Journal of Kunming Medical University,
[17]	Liu Yue Bo . . Journal of Kunming Medical University,
[18]	Hu Hai Yan . . Journal of Kunming Medical University,
[19]	Liu Jian Xing . . Journal of Kunming Medical University,
[20]	. . Journal of Kunming Medical University,